Swedish Orphan Biovitrum AB (publ) (OTCMKTS:BIOVF) – Equities researchers at Jefferies Financial Group dropped their FY2019 earnings per share estimates for Swedish Orphan Biovitrum AB (publ) in a research note issued on Wednesday, July 17th. Jefferies Financial Group analyst E. Yang now forecasts that the company will post earnings per share of $1.18 for the year, down from their previous estimate of $1.30. Jefferies Financial Group also issued estimates for Swedish Orphan Biovitrum AB (publ)’s Q4 2019 earnings at $0.43 EPS, FY2020 earnings at $1.58 EPS, FY2021 earnings at $1.75 EPS, FY2022 earnings at $1.92 EPS and FY2023 earnings at $2.02 EPS.
BIOVF has been the subject of a number of other research reports. Deutsche Bank increased their target price on eBay from $42.00 to $46.00 and gave the company a “buy” rating in a report on Thursday. Zacks Investment Research raised Hallmark Financial Services from a “hold” rating to a “buy” rating and set a $16.00 target price for the company in a report on Friday.
About Swedish Orphan Biovitrum AB (publ)
Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haemophilia, immunology, and genetic and metabolic diseases. The company offers Elocta to treat haemophilia A; and Alprolix to treat haemophilia B.
Featured Article: How to interpret the current ratio
Receive News & Ratings for Swedish Orphan Biovitrum AB (publ) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Swedish Orphan Biovitrum AB (publ) and related companies with MarketBeat.com's FREE daily email newsletter.